2 completed, 1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Advanced Renal Cell Carcinoma (aRCC): new trials by email Literature Review of Advanced Renal Cell Carcinoma (aRCC) trials Research Report on Advanced Renal Cell Carcinoma (aRCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Fianlimab, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Recruiting | Brian Rini | 120 | 2026-04-29 | 2026-09-04 |
| Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma Envafolimab Injection, Axitinib Tablets - Advanced Renal Cell Carcinoma (aRCC) | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 30 | 2025-09-01 | 2025-09-08 |
| Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy - Advanced Renal Cell Carcinoma (aRCC) | Completed | Bristol-Myers Squibb | 327 | 2024-02-19 | 2025-11-06 | |
| Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination Advanced Renal Cell Carcinoma (aRCC) | Completed | Ipsen | 281 | 2021-09-09 | 2024-12-17 |
Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Nivolumab (2) · Axitinib (1) · Ipilimumab (1) · cemiplimab (1) · envafolimab (1) · pembrolizumab (1)
Brian Rini (1) · Bristol-Myers Squibb (1) · Ipsen (1) · Peking Union Medical College Hospital (1)
United States (2) · United Kingdom (1)
Brian Rini, MD (1)